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Nanomedicines: Nano based Drug 




Nanomedicine and nano delivery systems, although relatively recent but 
 fast-developing technology is one where nanoscale materials are used to function 
as diagnostic tools or to deliver therapeutic agents to specifically targeted sites in a 
controlled manner. It also provides many advantages in the management of human 
diseases. Recently, there has been a range of excellent uses of nanomedicine as 
chemotherapeutic agents, biological agents, immunotherapeutic agents, etc., for 
treatment of different diseases. In this chapter we discuss the recent developments 
and insights obtained in the field of nanomedicine. It provides a review of the 
numerous nano-based drug delivery systems that enhance the efficacy of new and 
old drugs. The new opportunities and challenges arising in the area of nanomedi-
cine from therapeutic viewpoint are also addressed.
Keywords: nanomedicines, nanoparticles, drug delivery systems, drug targeting, 
natural products added
1. Introduction
Human beings have been widely utilizing plant-based natural products as 
medicines against various diseases since ancient times. Many medicines are derived 
primarily from herbs, based on traditional knowledge and practices. Currently about 
25% of the available therapeutic compounds and their derivatives are derived from 
natural resources [1, 2]. Natural compounds have impressive characteristics, such as 
exceptional chemical versatility, chemical and biological properties of macromolecu-
lar specificities and less toxicity. These thus constitute them as leads in the discovery 
of novel drugs [3]. In spite of several advantages, pharmaceutical companies are 
hesitant to commit to more in drug discovery and drug delivery systems based on 
natural compounds due to concerns associated with biocompatibility, toxicity, large 
size and targeted delivery, etc., and many natural compounds not even clearing the 
clinical trial phases [4, 5]. Hence, this presents a greater challenge of using them as 
medicine. Thus alternatively available libraries of chemical compounds are being 
explored to discover novel medicines. Various techniques like nanotechnology play 
substantial role in advancing drug formulations, targeting, efficient release and 
delivery with immense success. Nanotechnology bridges the barrier between physical 
and biological sciences by providing nanostructures with potential to fill the lacunae 
existing in various fields of sciences and in particular in the field of medicine.
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The use of nanotechnology in the production of efficient medicines has been 
recognized as a key enabling technology, capable of delivering fresh and creative 
therapeutic approaches to address unmet medical demands [6]. The use of nano-
technology for medical purposes is referred to as nanomedicine [7] and nano-
materials are used for prevention, early diagnosis or treatment of a wide range of 
diseases with high specificity, efficacy, and personalization, to improve quality of 
life of patients. Owing to their small scale, nanomaterials have novel physicochemi-
cal properties, distinct from those of their traditional bulk chemical counterparts. 
Such properties significantly improve a range of opportunities in drug develop-
ment. These physicochemical properties of nanoformulations can lead to pharma-
cokinetics/pharmacodynamics being changed, namely the delivery, absorption, 
removal and metabolism, the potential for more easily breaching biological barriers 
and their persistence in the environment and the human body.
The key component of nanomedicines are nanoparticles (NPs) and currently 
wide range of nanoparticle types exist depending on their structural features such as 
spheres [8], rods [9], wires [10], stars [11], sheets [12], multipodes [13], cages [14], etc. 
These particles can efficiently carry and deliver therapeutic agents as well as imaging 
and sensing agents to targeted sites. Nanoparticle carriers or nanocarriers have many 
advantages in medicine. First, they allow stable aqueous dispersions of active but 
poorly water-soluble therapeutic agents for delivery into the biological environment. 
Second, their structure, scale, shape and surface properties can be finely designed 
to protect the encapsulated agent when incorporated into the biological world and 
prevent it from degradation by various endogenous defense mechanisms including, 
immunodegradation, enzymatic degradation, reticuloendothelial system sequestra-
tion (RES) in the bloodstream, acid hydrolysis, lung mucociliary clearance, etc.
2. Delivery system of nanoformulations
Delivery of nanomedicines can be by intracellular transport, epileptic transport 
and other types. Intercellular transport is facilitated and regulated through intracel-
lularization, transporter mediated endocytosis, and permeation by interactions 
through particle size and/or cell surface [15, 16]. In addition, a smaller nanomedi-
cine particle size improves intercellular transport which facilitates cell permeation 
and affects nanomedicine absorption, dissemination, and excretion. In fact, cell 
internalization by transporter-mediated endocytosis depends on the size of the 
nanomedicine molecule. Similarly in large particle sized nanomedicine, opsoniza-
tion occurs quickly and its removal from the blood is facilitated by endothelial 
macrophages. The susceptibility of nanomedicinal cell surface transporters to 
nanomedicinal products has been reported to vary depending on the particle size of 
nanomedicinal products, and this can also impact the effective removal by macro-
phages of large particles from the blood. Nanomedicines composed of non-charged 
polymers, surfactants, or polymer coatings that degrade in vivo, associate with cell 
surface receptors or ligands because of their hydrophilicity to increase permeability 
or promote internalization of nanomedicines. In addition, through interacting 
with bioadhesive polymers or chelates, nanomedicines improve the intracellular 
transport of active pharmaceutical ingredients. Improved intracellular movement 
of active pharmaceutical ingredients coupled with various proteins, antibodies and 
other in vivo polymers is due to the opening of tight junctions and/or improved 
membrane permeability. In particular, the incorporation of anti-cancer agents with 
such a role would increase the effectiveness of chemotherapy, including the treat-
ment of brain tumors that are immune to drugs associated with close junctions, 
the targeting of tumor cells and the routine targeting of cells. Using such a strategy 
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for nanomedicines, cytotoxicity against normal cells can be minimized and greater 
anti-cancer efficacy will be achieved. Decrease in intake of nanomedicines in the 
lungs through inhalation results in an improvement attributable to decreased dete-
rioration and absorption by lung mucosa or macrophages, resulting in improved 
product processing period and product transfer to goal. The enhanced permeability 
and retention (EPR) effect improves anti-cancer efficacy by enhancing tumor per-
meation and retention time. The effect of the EPR also makes it possible to directly 
transmit nanomedicines to target tissue by combining an antigen, enzyme, peptide, 
or polysaccharide that can be used to modify the delivery of nanomedicines to 
target tissues via receptor/ligand interactions or other physiologically sensitive 
cell regulation interactions, drug efficacy modification or adverse reactions. There 
is improved longevity of hydrophilic-coated nanomedicines, preventing their 
opsonization or accumulation in the mucus. Nanomedicines can be retained in vivo, 
e.g. in the lung tissue for extended periods of time by particle size, by inhibiting 
macrophage-induced or mucosal disturbance and escape elimination by mucus cili-
ates, which may lead to deterioration or macroscopic consequences of lung mucosa 
[17]. Thus, a number of formulations have been designed that use delivery pathways 
that can regulate the pharmacokinetics and pharmacodynamics of nanomedicines.
3. Nanomaterial based delivery system
Nanotechnology in drug delivery has the potential to overturn the treatment of 
various diseases such as cancer, diabetes, neurodegenerative diseases, vascular dis-
eases, etc. [18]. In the market for sale, nanotechnology based formulations are largely 
parenteral, with some intended for oral administration [19]. It is hoped that a signifi-
cant number of preclinical and clinical trials would lead to the production of novel 
nanotherapeutics intended for non-parenteral delivery routes, such as pulmonary, 
nasal, vaginal, ocular, and dermal delivery routes. Of special concern to drug delivery 
systems (European Commission/ETP) [20] is the option of delivery and the obstacles 
to be addressed. Over time, various formulations based on nanoparticles have been 
developed to enhance the delivery mechanism of drugs, such as discussed below:
3.1 Polymeric nanoparticles
The most widely used chemical nanoparticles are constructed from synthetic 
polymers as natural polymers result in low reproducibility and controlled release 
actions for the trapped products, leading to variability in purity and batch-to-batch 
quality. At the other side, synthetic polymers with good to batch reproducibility 
and purity are available which facilitates the modification of the pattern of drug 
release from polymeric nanoparticles [21]. Nanoparticles formulated with synthetic 
polymers have been widely studied for drug distribution/delivery. In double emul-
sion methods hydrophilic moieties will encapsulate onto synthetic polymer-based 
nanoparticles, as it is not easy to maintain activity in unfavorable environment. 
Various synthetic polymers reported for drug delivery with biodegradable aliphatic 
polymers such as polylactide (PLA), poly lactide-co-glycolide, copolymers (PLGA) 
and poly (ε-carpolactone), as well as non-biodegradable polymers like polyacrylates 
and poly (methyl methacrylate) are used widely [22]. Polymer nanoparticles can 
efficiently shield unstable drugs from deterioration/degradation, thus avoiding 
the side effects of toxic medications. Natural polymeric nanoparticles consist of 
polymers of natural products like alginate, chitosan, albumin and gelatin [22]. 
Application of polymeric nanoparticles with therapeutic drugs such as dexametha-
sone or alpha-tocopheryl succinate can be used to avoid the cisplatin ototoxicity 
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due to treatment with chemotherapy. Nanoparticles, trapping, transporting and 
ultimately spreading dexamethasone or alpha-tocopheryl succinate are capable of 
partially preventing large-dose ototoxicity of CDDP [23]. However, when admin-
istered systemically for long periods of time, these least soluble drugs have serious 
side effects. In the hydrophobic cavity of nanoparticles, the integration of such 
pharmaceutical products provides the requisite results in vitro and in vivo. Few 
popularly marketed formulations of the polymeric nanoparticles are Decapeptyl®, 
Gonapeptyl Depot®, Enantone Depot®, and Abraxane [24, 25].
3.2 Lipid nanoparticles
Lipid nanoparticles that are prepared with a solid matrix are called solid lipid 
nanoparticles (SLNs). These are constructed from nanoemulsions of oil in water 
with the utilization of a solid lipid. The first generations of SLNs were formed in 
the early 1990’s [26]. The benefits associated with SLNs include cheap raw materi-
als, usage of physiological lipids, avoidance of organic solvents, ease of scale-up, 
strong biocompatibility, enhancement of bioavailability, safety of vulnerable molds 
from environmental hazards and regulated drug release [27]. Using ultrasonic melt 
emulsification [28], ciprofloxacin (CIP)-loaded SLNs have recently been formulated 
with powerful antibacterial action. These were produced with a scale ranging from 
165 to 320 nm and a polydispersity index with high trapping efficiency falling 
between 0.18 and 0.33. A controlled-release pattern of different lipids was shown 
by CIP release showing the full burst reaction, which contributes to the drug’s rapid 
release. For 120 days this composition of CIPSTE was found to be stable at room 
temperature. SLNs for different routes of delivery, such as oral [29], dermal [30], 
pulmonary [31], ocular [32] and rectal [33], have been extensively tested in vitro 
and in vivo. Nano base and nano pearl are marketable SLN formulations [34].
3.3 Dendrimers
Dendrimers are special three-dimensional, hyper-branched, globular nano-
polymeric structures. Attractive features such as water solubility, nano scaled 
size, narrow polydispersity index, modifiable molecular structure, internal cavity 
and several peripheral functional groups separate these from other nano systems. 
Terminal functionality serves as a platform for the conjugation and targeting of 
drugs. Such peripheral functional groups also provide them with tailor-made 
properties which improve their versatility [35]. The most commonly studied den-
drimer for drug delivery is polyamidoamine. It’s synthesis starts with the amine 
group, which interacts with methyl acrylate and contributes to the formation of two 
new branches of dendrimer terminated by ester. The amine-terminated dendrimer 
‘Full-generation’ may be formed by subsequent amidation of the methyl ester with 
ethylene diamine. PAMAM dendrimers are non-immunogenic, biocompatible and 
water-soluble, and have functional terminal amine groups that can be altered to 
targeting drugs [35]. Dendrimers have been widely investigated for biodelivery 
via transdermal, nasal, ocular, and pulmonary pathways, in addition to improving 
solubility. Many of the synthetic cationic polymers such as amidised acid-labile allow 
different cargo delivery [36]. Changing their structure could solve toxicity-related 
problems [35]. A recent study showed that arginine terminated peptide dendrimers, 
along with sonophoresis, can significantly increase ketoprofen’s transdermal pen-
etration [37]. The findings revealed that the use of peptide dendrimer and applica-
tion of ultrasound has worked synergistically. In vitro experiments have found 
that dendrimer and ultrasound-mediated drug permeation contributes to higher 
active drug plasma concentration as opposed to passive diffusion. Transdermal 
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administration of ketoprofen with A8 dendrimer demonstrated similar drug absorp-
tion and oral path plasma concentration [37]. Commercially available dendrimers of 
poly-propylenemine (PPI, AstromolR, DAB) [38] and polyamidoamine (PAMAM; 
Starburstk) have been the most usually explored for pharmacological use [38, 39].
3.4 Nanoemulsion
Nanoemulsions are a fascinating colloidal drug delivery mechanism, thermo-
dynamically stable and filtration-sterilizable [40, 41]. There are heterogeneous 
mixtures of oil droplets in aqueous media resulting in nano droplets with a small 
scale distribution. The resultant nanoemulsions are analyzed as translucent or clear, 
isotropic and supported by the suitable surfactant [42]. Three types of nanoemul-
sions can be developed:
a. water in oil nanoemulsion
b. oil in water nanoemulsion
c. bi-continuous nanoemulsion
The most detailed function of nanoemulsions is to mask the unpleasant taste 
of oily liquids. These also provide long-term drug action and prevention from 
hydrolysis and oxidation. These nanoformulations can therefore be identified as an 
efficient and impregnable delivery option with high bioavailability. Nanoemulsions 
are currently being explored extensively to target different photosensitizers, 
anticancer drugs, or therapeutic agents. Such nanoformulations propose a number 
of applications such as drug delivery, biologic diagnostics and chemical agents [43]. 
In 2016, Simion et al. developed targeted dexamethasone-loaded P-selectin lipid 
nanoemulsions to minimize vascular inflammation [44]. Prepared formulations 
have been described for physicochemical assays. In their study, nanoformulation 
was found to be efficient in both in vitro and in vivo experiments. It reduces the 
function of the endothelium activation selectively and thereby the inflitration 
of monocytes, resulting in a substantial reduction in inflammation of the lungs 
in a model animal mouse. Examples of nano-emulsion formulations are Norvir 
(Ritonavir), Restasis, Gengraf (Cyclosporin A), Etomidat-Lipuro (Etomidate), 
Ropion (Flurbiprofenaxtil), Diprivan, Troypofol (Propofol), Limethason 
(Dexamethasone) and Liple (Alprostadil palmitate) [45].
3.5 Nonstructured lipid carriers (NLC)
Nonstructured lipid carriers comprise the nanosystems of the second generation, 
consisting of solid lipid embedded into liquid lipids [46]. These nano carriers allow for 
a strong immobilization of therapeutic agents and avoid particle coalition of particles 
relative to emulsions [47, 48]. Therefore, because of the liquid oil droplets in a solid 
matrix, their drug loading potential is increased relative to SLNs. Biodegradability, 
lower toxicity, controlled release, drug tolerance and avoidance of organic solvents 
during manufacturing are among the beneficial effects of NLC on polymeric nanopar-
ticles. NLCs have been extensively studied for hydrophobic and hydrophilic drug 
transport in recent years. The NLCs are developed to satisfy industrial specifications 
related to certification and registration, basic infrastructure, scale-up and low cost 
criteria [49]. The presence of multiple consumer goods reflects the carrier’s success 
story. Numerous other NLC products, including NLC repair cream and NLC restora-
tion cream, are commercially available. For the treatment of different diseases, NLCs 
Alternative Medicine - Update
6
were explored through various routes of administration viz. oral, nasal, and parenteral 
[50]. Fluconazole-loaded NLCs were constructed using probe ultrasonication method 
and studied for antifungal activity on various Candida species. A substantial decrease 
in maximum inhibitory concentration (MIC) for all classes of Candida was observed 
using fluconazole NLCs. It is also mentioned that Candida albicans is more susceptible 
to fluconazole loaded NLCs than Candida Parapsylosis, Candida glabrata [51].
3.6 Nanogel
Nanogels, comprised of flexible hydrophilic polymers, can be prepared as plain 
gels [52]. Upon swelling, the drug can be randomly inserted into the nanogel. As a 
result, the gel collapses, resulting in the creation of solid, compact nanoparticles 
with reduced solvent amount. Nanogels provide novel applications for polymer-
based drug carrier systems due to their biocompatibility, high moisture content and 
suitable mechanical properties. These gels have expanded polyvalent bioconjugation 
surface area and an internal network for biomolecule trapping. Physical encapsula-
tion of bioactive compounds in the polymeric interlock along with their releasing 
pattern has been widely explored as a targeted mode of drug delivery [53]. Several 
approaches for the preparation of nanogels include micro-molding and photolitho-
graphic methods, continuous micro fluidics, modification of biopolymers, and het-
erogeneous living/controlled radical and free radical polymerizations [54]. Several 
criteria are required for designing and manufacturing of an efficient nanogel drug 
carrier system for therapeutic application. The consistency of nanogels for long-
lasting blood circulation is one significant criterion. Another extraordinary novel 
feature that can detect receptors on infected cells is the bioconjugation of nanogel 
surfaces with particular ligands. Eventually, the biodegradability of nanogels should 
not only control the release of the drug for the required amount of time, but also 
make it possible to eliminate the empty system after the release of the drug [54]. In 
a recent study, topical delivery of chitin nanogel loaded with clobetasol is reported. 
This nanogel demonstrated exceptional toxicity against THP-1 and HaCaT cell lines 
by MTT assay. Nanoformulation demonstrated significant anti-inflammatory ability 
with an average inhibition of LOX and COX activities in THP-1 cells of 70 percent 
and 65 percent. Increased transdermal flux has been obtained from permeation 
studies of in vitro skin. Antipsoriatic activity conducted in vivo on imiquimod model 
demonstrated the value of nanogel for the topical application of clobetasol for pso-
riasis. Some selected and marketed nanogels are Sane Care Nanogel, Zyflex Nanogel, 
Augen Nanogel Eye-care Gel, Skin Beautiful Brightening Nanogel [55], and Oxalgin.
3.7 Nanocapsule
Nanocapsule consists of either liquid or solid core in which drug is loaded and 
encapsulated by membrane of synthetic or natural polymers [56, 57, 58]. Lipid core 
nanocapsules are prepared by the precipitation method. Prepared nanoparticles have 
been tested for physical, chemical and biological characteristics. The most important 
characteristics to note during their synthesis are particle size and distribution. This can 
be calculated through multi-angle laser light scattering in a superconducting quantum 
interference instrument through X-ray diffraction, X-ray photoelectron spectroscopy, 
Transmission Electron Microscopy (TEM) and Scanning Electron Microscopy (SEM) 
[57]. Chemically stable, biocompatible and readily reproducible are industrial bioactive 
nanocapsules. Because of their coating, which protects the encapsulated material from 
unenviable effects, such as dissolving the liquid and avoiding the release of active com-
ponents, they have captured the attention of research groups. In biomedical research, 
agrochemicals, sanitizing materials, cosmetics and water treatment, nanocapsules have 
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a wide range of biomedical applications. In addition, the effectiveness of such medica-
tions has also been studied for cancer treatment [59], radiotherapy [60], self-healing, 
contagion [78] and for use in food and agriculture. New developed nanocapsules will 
open new avenues of research and development for the delivery of bioactive com-
pounds to target tissues in the future [57, 58]. Due to their ability to destroy colon cancer 
cells, resveratrol-charged lipid-core-nanocapsules (RSV-LNC) were developed and 
characterized. Constant and controlled drug release has been confirmed by the RSV-
LNC. Increased anticancer activity in HT29 cancer cells compared to free RSV resulted 
in RSV incorporated in the nanocapsule. RSV-loaded nanocapsules have a promising 
potential for enhancing therapeutic effectiveness in colon cancer cells based on in vitro 
evaluation. In order to authenticate the improved behavior of RSV nanoformulations, 
more experiments on animal models are nevertheless proposed. SOLUDOTS-PTX 
(Lipid Nanocapsules of Paclitaxel) is currently in clinical trials.
3.8 Nanosponges
Nanosponges have drawn the interest of drug delivery scientists in pharmaceuti-
cal science as they have the capacity to load both hydrophilic and lipophilic moieties 
[61, 62]. These are thin, non-toxic, porous colloidal structures of scaffolds that 
have multiple cavities where drug molecules can be stuck. In the processing of these 
nanocarriers, α-cyclodextrins are the most commonly used. It is possible to investi-
gate different crosslinkers in their development, such as hexamethylene di-isocya-
nate, carbonyl di-imidazole, pyromellitic dianhydride, diphenyl carbonate, etc. In 
water as well as in organic solvents, these structures are insoluble [63], self-sterile 
[64, 65] and stable up to 300° C and pH range of 2–11. Using ultrasound-assisted 
synthesis techniques, Trotta and colleagues produced cyclodextrin nanosponges 
[86] and examined them for anti-tumor drugs [66]. Efavirenz is a class II drug, a 
non-nucleoside reverse transcriptase inhibitor widely used for HIV [67]. This medi-
cine, however, exhibits less solubility and reduced bioavailability. Beta-cyclodextrin 
cross linking with carbonates in variable ratios was performed to increase the 
solubility and dissolution of this compound. Some of the advertised formulations of 
nanosponge are Glymasason, Prostavastin, Brexin and Mena-gargle [68, 69].
3.9 Inorganic nanoparticles
Silver, gold, iron oxide and silica are included in inorganic nanoparticles. 
Nevertheless, only a few nanoparticles have been approved for clinical use, while 
most of them are still in the clinical trial stage. Metal nanoparticles, silver and gold, 
have different properties such as SPR (surface plasmon resonance) that liposomes, 
dendrimers, micelles do not exhibit. They show a variety of benefits when it comes 
to surface durability, such as decent biocompatibility and flexibility. Studies of their 
delivery-based actions have not been able to establish whether their toxicity is based 
to the particulate or ionized form; and while two mechanisms, such as paracellular 
transport and transcytosis, have been suggested, there is inadequate evidence on 
their in vivo transmission and uptake mechanisms [70]. Drugs can be conjugated by 
ionic or covalent bonding and physical absorption to gold nanoparticles (AuNPs) 
surfaces and can be transmitted and regulated by biological stimulation or light 
activation [71]. Silver nanoparticles display antimicrobial activity however, as far 
as drug distribution is concerned, very few experiments have been performed, e.g. 
Prusty and Swain [72] synthesized a spongy polyacrylamide/dextran nano- hydrogel 
hybrid structures with covalently attached silver nanoparticles for ornidazole 
production, resulting in an in vitro release of 98.5 percent [72]. Likewise, in another 
study, iron oxide nanoparticles were synthesized using a laser pyrolysis process and 
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protected by Violamycin B1 and antracycline antibiotics and tested against MCF-7 
cells for their cytotoxicity and anti-proliferation properties, compared with com-
mercially available iron oxide nanoparticle and showing promising results [73].
3.10 Quantum dots
Quantum dots (QDs) are regarded as semiconductor nanocrystals with a diameter 
ranging from 2 to 10 nm with their optical characteristics, such as absorbance and 
photoluminescence being size-dependent [74]. QDs have received significant inter-
est in the field of nanomedicine, because, unlike traditional organic dyes, QDs pose 
emissions in the near-infrared region (< 650 nm), a very advantageous phenomenon 
in the field of biomedical imaging, due to low tissue absorption and decreased light 
dispersion [75]. Furthermore, the same light source can excite QDs with different 
sizes and/or compositions resulting in separate emission colors over a wide spectral 
range [76, 77]. In this way, QDs are quite attractive to multiplex imagery. QDs have 
been extensively studied in the field of medicine as targeted delivery of drugs, sen-
soring and imaging agents. A large number of studies on the use of QDs as contrast 
agents for in vivo imaging are currently available in the literature [78, 79]. Han et al. 
[80] have produced a novel fluorophore for intravital cytometric imaging based on 
QD conjugate antibodies coated with norborne-displaying polyimidazole ligands. 
This fluorophore has been used for the in vivo marking of bone marrow cells. The 
investigators found that fluorophore has been able to diffuse across the bone marrow 
and mark rare cell types, such as hematopoietic stem and progenitor cells [80]. Shi 
et al. (2015) [79] have produced a multifunctional biocompatible graphene oxide 
quantum dot protected by a magnetic nanoplatform for the detection/diagnosis of 
specific tumor cells of liver cancer (glypican-3-expressing hep G2). According to the 
scientists, the adhesion of an anti-GPC3 antibody to the nanoplatform resulted in a 
systematic isolation of hepG2 hepatocellular carcinoma cells from blood samples [79]. 
The continuous and/or controlled release of therapeutic agents can also have benefits 
from QDs. This behavior can be achieved by active stimuli by light, wind, radio 
frequency or magnetic fields [81, 82] as far as controlled release is concerned. Olerile 
et al. [83] have developed a theranostic framework as a multi-functional parenteral 
system that focuses on the co-loading of QDs and anti-cancer drugs in nanostructured 
lipid carriers. The nanoparticles were spherical with a higher paclitaxel encapsulation 
potential (80.7 ± 2.11 percent) and a 77.85 percent tumor growth inhibition score. The 
authors observed that the device was able to monitor and identify H22 tumor cells 
precisely [83]. Cai et al. [84] have produced pH-responsive quantum dots based on 
ZnO quantum dots coated with PEG and hyaluronic acid to be stable under physiologi-
cal conditions and for targeting specific HA-receptor CD44 cells. This nanocarrier was 
also assessed for doxorubicin’s (DOX) sustained release. At physiological pH, these 
carriers were stable and DOX was loaded into the carrier and the complex form of Zn2+ 
ions or PEG conjugation. DOX was only released from the tumor cells under acidic 
intracellular conditions due to disturbance of ZnO QDs. The investigators found that 
the combination of DOX and ZnO QD [84] enhanced the anticancer function.
4. Natural product based drug delivery system
Natural product-based materials are currently considered to be the key  ingredients 
in the preparation and processing of new nanoformulations as they have interesting 
features such as biodegradability, biocompatibility, availability, renewability and 
low toxicity [85–87]. In addition to the aforementioned properties, biomaterials are 
largely capable of undergoing chemical modifications, ensuring unique and desirable 
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properties for potential nanomedicine uses [88, 89]. For example, nanoparticles of 
metals, metal oxide and sulfides have been recorded to be synthesized using dif-
ferent microorganisms, including bacteria, fungi, algae, yeast, etc., [90] or plant 
extracts. Microorganism that assists the synthesis process is prepared in the adequate 
growth medium and then mixed with a metal precursor and left for incubation to 
form the nanoparticles either intracellularly or extracellularly [91–93]. Similarly, 
plant extracts are used for synthesis in which the extract is mixed with the metal 
precursor and incubated further at room temperature or boiling temperature for 
a definite time or exposed to light as an external stimulus [94]. Currently, natural 
product-based materials are considered essential ingredients in the preparation and 
production of nanoformulations as they have fascinating characteristics such as 
biodegradability, biocompatibility, sustainability, renewable energy and low toxic-
ity [85, 86, 95]. In addition to the above mentioned properties, biomaterials are, for 
the most part, capable of undergoing chemical modifications, guaranteeing them 
special and attractive properties for future applications in the field of nanomedicine 
[89, 96, 97]. Nanoparticles, especially the silver nanoparticles have been prolifically 
studied in vitro for their antibacterial, antifungal, and cytotoxicity potential [98, 99]. 
Nanocarriers such as crystal nanoparticles, liposomes, micelles, polymeric nanopar-
ticles, solid lipid nanoparticles, superparamagnetic iron oxide nanoparticles and 
dendrimers are formulated for natural product based drug delivery. Gupta et al. [100] 
synthesized chitosan-based nanoparticles loaded with Paclitaxel (Taxol) extracted 
from Taxus brevifolia for cancer therapy applications, and used them to treat various 
forms of cancer. The drug loaded with nanomedicines exhibited better efficacy with 
sustained release, high cell absorption and decreased hemolytic toxicity compared to 
pure Paclitaxel [100]. Chang et al. [101] developed a heparin/berberine conjugate to 
improve the suppressive development of Helicobacter pylori, thus reducing cytotoxic 
effects in infected cells. In a study conducted by Dian et al. [102], polymeric micelles 
were used to deliver Quercetin (polyphenol) and the results showed that these 
micelles could provide continuous release for up to 10 days in vitro, with continuous 
plasma levels and increased complete in vivo drug accessibility. Spillmann et al. pro-
posed a multifunctional liquid crystal nanoparticles device as intracellular fluorescent 
imaging and doxorubicin distribution in which nanoparticles were functionalized 
with transferrin. Daunorubicin is a natural product extracted from a number of 
wild strains of Streptomyces, doxorubicin (DOX) is a hydrolated version of it used in 
chemotherapy [103]. Within the endocytic vesicles of HEK 293 T/17 cells, cellular 
uptake and continuous liberation have been achieved. For intracellular transport, 
perylene was used as a chromophore to chase particles and encapsulated compounds 
[104]. Liposomes are studied mostly, and have been used in various formulations for 
the delivery of natural products like Resveratrol, Curcumin, etc. [105, 106].
In addition, it can be seen that the sustained release mechanisms of naturally 
occurring therapeutic agents are a crucial method for increasing the biological 
efficacy of these agents and addressing their drawbacks by introducing new options 
for chronic and terminal disease management [107–110].
The global demand for plant-derived pharmaceuticals will rise from $29.4 billion (as 
in 2017) to around $39.6 billion in 2022 with a compound annual growth rate (CAGR) 
of 6.15% in this timeframe (BCC-Data), according to BBC Report. Any of the nano-
structure-based materials included in this section have already obtained FDA clearance.
5. Challenges and opportunities
While there have been a large number of nanomedicine-related studies and 
tests, only a handful have advanced to market-related review and once again a 
Alternative Medicine - Update
10
smaller handful have earned final clearance. The conversion of fundamental science 
into clinical practice was less than 10 percent, based on some reports [111, 112]. 
Thus, drugs that travel through what is known as the ‘valley of death’ do not seem 
convenient. This will lead to a time-consuming, lengthy, futile series of reviews, 
escalating the expense of health care as a whole [113]. Perhaps the reasons for such 
an undesirable state of affairs lie in multiple fields and procedure facets. One of 
the key problems involves nanoparticles’ in vivo behavior, which is expected to be 
somewhat different from their in vitro behavior. The key problems that need to be 
extensively explored using various animal (in vivo) models are cellular interactions, 
tissue transfer, diffusion, and biocompatibility. It is not simple or cheap to perform 
such tests to provide adequate proof of effectiveness and protection. Another obstacle 
for tumor-targeted nanoformulations in particular is the heterogeneity and hetero-
geneous nature of tumors. Different gene expression profiles, molecular patterns 
and degree of drug resistance between different tumors may impede penetration and 
decrease the efficacy of tumor-targeted NPs [114, 115]. This challenge could lead to 
an unsuccessful clinical trial (despite promising animal preclinical data) and to rejec-
tion of the nanoformulations examined. Relevant drug penetration into tumors, the 
efficacy of the release of drugs into the target cells, and the quality of the drug loaded 
nanoparticles, are other factors that involve a precise professional experimentation 
[114]. Owing to time and money problems, this comprehensive research may not be 
possible in all biomedical laboratories which itself is another concern. The multifunc-
tional structure and operation of some nanoformulations could be another obstacle 
on the road to nanoformulation acceptance. Many investigative nanoformulations 
have a hybrid structure and contain separate diagnostic and therapeutic components. 
Different experiments are required to demonstrate the protection of such systems, 
and the long-term biocompatibility of such systems is not yet clear [116, 117]. 
Regarding this issue, the regulatory authorities have different restrictions, and it will 
take time-consuming and costly regulatory studies to be sure of the long-term safety 
of these theranostic nanoformulations. Many of the classical approaches for nano-
formulation synthesis are already incomplete and need to be more developed and 
optimized. Batch-to-batch variance is another problem that can hamper the develop-
ment of enough stocks of nanoformulations for market approval to be achieved. The 
updating of production methods and the highly accurate characterization of nanofor-
mulations are expected to be laborious, time-consuming and expensive [116, 118].
In spite of all the above-mentioned obstacles, the demand for nanopharmaceuticals 
and nanomedicines will continue to expand over the next few years, primarily thanks 
to developments in bionanotechnology and nanoengineering, the implementation 
of explicit guidelines on new nanotechnology-based products, more support from gov-
ernment organizations, more consensus on environmental issues and the creation of 
collaborations between nanomedicines startups and leading pharmaceutical compa-
nies [119]. In other words, in order to convince investors about the value of nanophar-
maceuticals and to improve the overall health and well-being of society, intellectual 
property and regulatory agencies need to change their approach to meeting the spe-
cific needs of nanomedicine and shorten their time to regulatory approval. However, 
in the case of nanodrugs, it is particularly important to consider the risks to health and 
the environment vis a vis it’s short-term gains. Another similarly significant aspect 
that has drawn researchers and companies’ interest is the increasing role that cancer 
plays in mortality and morbidity statistics worldwide As in 2018, FDA earned the most 
approvals for oncology drugs [120, 121]. This, and the large number of other cancer-
related pharmaceuticals licensed over the past few years, shows not just the patients’ 
desperate need for better cancer treatment, but also the massive cancer care market. 
There is still tremendous hope for the application of chemotherapy and photothermal 
or photodynamic treatment. These, though, are variations of products, which could be 
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easier to progress to complete clearance. Diseases affecting the immune system are also 
very important for the pharmaceutical industry. These applications include stimulat-
ing the immune system to combat infections and cancer, but also to down-regulate the 
immune system to combat autoimmune diseases and allergies. Overall, it is believed 
that the rising rate of cancer-related deaths will be driving the anticipated increase in 
the size of the global nanomedicine market in the coming years.
6. Conclusion
Initially, the use of nanotechnology was mostly based on improving the solubility, 
absorption, bioavailability and controlled release of drugs, but now a wide range of 
nanodimensional tools are included that can be used to diagnose, precisely deliver at 
target, sense or activate material in the living system. By using nanocarriers formulated 
with gold, silver, cadmium sulphide, and titanium dioxide polymeric nanoparticles 
along with solid lipid nanoparticles, nanogels, liposomes, micelles, iron oxide nanopar-
ticles, and dendrimers, the efficacy of the natural products has greatly improved. 
One of the major interests in the advancement of nanomedicine in recent years is 
the convergence of therapy and diagnosis (theranostic) as an example of cancer as a 
disease model. Since the 1990s, there has been a remarkable growth in the number of 
FDA-approved nanotechnology-based products and clinical trials, including synthetic 
polymer particles; liposome formulations; micellar nanoparticles; nanocrystals and 
many others frequently associated with drugs or biologics. Although regulatory frame-
works for nanomedicines along with safety/toxicity tests will be the focus of further 
research in the future, the way we discover and deliver drugs in biological systems has 
already revolutionized nanomedicine. Thanks to advances in nanomedicine, the ability 
to deliver, and even targeted delivery, has also become a reality.
© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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